Emerging Infectious Diseases (Mar 2021)

Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs

  • Hamzah Z. Farooq,
  • Daniela M. Cirillo,
  • Doris Hillemann,
  • David Wyllie,
  • Marieke J. van der Werf,
  • Csaba Ködmön,
  • Vlad Nikolayevskyy

DOI
https://doi.org/10.3201/eid2703.204418
Journal volume & issue
Vol. 27, no. 3

Abstract

Read online

We surveyed availability of phenotypic drug susceptibility testing for drug-resistant Mycobacterium tuberculosis in Europe. Of 27 laboratories, 17 tested for linezolid, 11 for clofazimine, 9 for bedaquiline, and 6 for delamanid during 2019. Our findings indicate that testing capacity for newer and repurposed tuberculosis drugs exists, but its availability is limited.

Keywords